Renal protection is a critical component of the therapeutic benefits provided by SGLT2 and GLP-1 RAs, particularly in patients with CAD and Type 2 Diabetes Mellitus (T2DM), where chronic kidney disease (CKD) is highly prevalent and significantly worsens prognosis [25]. This evidence concerns the gene GCG and type 2 diabetes mellitus.